CRISPR gene editing used to create 'Ready-Made' cancer therapy
Disease control
Terminated
This study tested a new type of cell therapy called CTX110 for adults with B-cell cancers that have returned or not responded to other treatments. The therapy uses immune cells (T cells) from healthy donors that are modified using CRISPR gene-editing technology to target cancer. …
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC